地西他滨的药理作用和临床评价

胡艳玲;傅得兴;胡欣

中国药学杂志 ›› 2008, Vol. 43 ›› Issue (02) : 81-84.

中国药学杂志 ›› 2008, Vol. 43 ›› Issue (02) : 81-84.
综述

地西他滨的药理作用和临床评价

  • 胡艳玲;傅得兴;胡欣
作者信息 +
文章历史 +

摘要

目的综述地西他滨的药理作用、药动学及临床评价。方法以近几年国内外代表性的论文来依据,进行分析、整理和归纳。结果与结论地西他滨的适应证为骨髓增生异常综合征,另有研究,其对镰状细胞性贫血、髓性细胞白血病以及一些实体瘤也有疗效。

关键词

地西他滨 / DNA甲基转移酶 / 药理作用 / 临床评价

引用本文

导出引用
胡艳玲;傅得兴;胡欣. 地西他滨的药理作用和临床评价[J]. 中国药学杂志, 2008, 43(02): 81-84

参考文献

[1] KANTARJIAN H,OKI Y,GARCIA-MANERO G,et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J] . Blood,2007,109(1):52-57. [2] DE VOS D,VAN OVERVELD W. Decitabine: a historical review of the development of an epigenetic drug[J] . Ann Hematol,2005,84 (Suppl 13):3-8. [3] ROSENFELD C S. Clinical development of decitabine as a prototype for an epigenetic drug program[J] . Semin Oncol,2005,32(5):465-472. [4] MOMPARLER R L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine) [J] . Semin Oncol,2005,32(5):443-451. [5] MANOHARAN A. Decitabine (SuperGen) [J] . Idrugs,2000,3(12):1525-1533. [6] JEAN-PIERRE J I,GARCIA-MANERO G,FRANCIS J G,et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies[J] . Blood,2004,103(5):1635-1640. [7] OKI Y,AOKI E,ISSA J P,et al. Decitabine-Bedside to bench[J] . Crit Rev Oncol Hematol,2007,61(2):140-152. [8] YANG A S,DOSHI K D,CHOI S W,et al. DNA Methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia[J] . Cancer Res,2006,66(10):5495-5503. [9] GHOSHAL K,DATTA J,MAJUMDER S,et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box,bromoadjacent homology domain,and nuclear localization signal[J] . Mol Cell Biol,2005,25(11):4727-4741. [10] LAVELLE D,VAITKUS K,HANKEWYCH M,et al. Effect of 5-aza-2′-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with theepsilon-,gamma-,and beta-globin promoters in Papio anubis[J] . Exp Hematol,2006,34(3):339-347. [11] SCOTT S A,DONG W F,ICHINOHASAMA R,et al. 5-Aza-2′-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation[J] . Leuk Res,2006,30(1):69-76. [12] MOMPARLER R L. Pharmacology of 5-Aza-2′-deoxycytidine (decitabine) [J] . Semin Hematol,2005,42(3 Suppl 2):9-16. [13] LEMAIRE M,MOMPARLER L F,BERNSTEIN M L,et al. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia[J] . Anticancer Drugs,2005,16(3):301-308. [14] CASHEN A,SHAH A,HELGET A, et al. A phase I pharmacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)[N] . Blood (ASH Annual Meeting Abstracts) 2005,106: Abstract 1854. [15] WIJERMANS P,LUBBERT M,VERHOEF G,et al. Low-dose 5-Aza-2*-deoxycytidine,a DNA hypomethylating agent,for the treatment of high-risk myelodysplastic syndrome:A multicenter phase Ⅱ study in elderly patients[J] . J Clin Oncol,2000,18(5):956-962. [16] WIJERMANS P W,LUBBERT M,VERHOEF G,et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients[J] . Ann Hematol,2005,84 (Suppl 13):9-17. [17] HACKANSON B,ROBBEL C,WIJERMANS P,et al. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies[J] . Ann Hematol,2005,84 (Suppl 13):32-38. [18] HENNESSY B T,GARCIA-MANERO G,KANTARJIAN H M,et al. DNA Methylation in haematological malignancies: the role of decitabine[J] . Expert Opin Investig Drugs,2003,12(12):1985-1993. [19] RUTER B,WIJERMANS P W,LUBBERT M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients[J] . Cancer,2006,106(8):1744-1750. [20] KANTARJIAN H,ISSA J P,ROSENFELD C S,et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study[J] . Cancer,2006,106(8):1794-1803. [21] MCKEAGE K,CROOM K F. Decitabine: in myelodysplastic syndromes[J] . Drugs,2006,66(7):951-958. [22] YEE K W,JABBOUR E,KANTARJIAN H M,et al. Clinical experience with decitabine in North American patients with myelodysplastic syndrome[J] . Ann Hematol,2005,84 (Suppl 13):18-24. [23] SABA H I,WIJERMANS P W. Decitabine in myelodysplastic syndromes[J] . Semin Hematol,2005,42(3 Suppl 2):23-31. [24] KOSHY M,DORN L,BRESSLER L,et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia[J] . Blood,2000,96(7):2379-2384. [25] JOSEPH D,MABEL K,LOUISE D,et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia[J] . Blood,2002,99(11):3905-3908. [26] SAUNTHARAJAH Y,HILLERY CA,LAVELLEe D,et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels,red cell adhesion,and hematopoietic differentiation in patients with sickle cell disease[J] . Blood,2003,102(12):3865-3870. [27] HASSANA F,GEORGE F A. Induction of fetal hemoglobin in the treatment of sickle cell disease[J] . Hematology,2006,2006(1):58-62. [28] ISSA J P,GHARIBYAN V,CORTES J,et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate[J] . J Clin Oncol,2005,23(17):3948-3956. [29] KANTARJIAN H M,O′BRIEN S,CORTES J,et al. Results of decitabine (5-aza-2′-deoxycytidine)therapy in 130 patients with chronic myelogenous leukemia[J] . Cancer,2003,98(3):522-528. [30] LUBBERT M,MINDEN M. Decitabine in acute myeloid leukemia[J] . Semin Hematol,2005,42(3 Suppl 2):38-42. [31] SCHRUMP D S ,FISCHETTE M R ,NGUYEN D M. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs,esophagus,or pleura[J] . Clin Cancer Res,2006,12(19):5777-5785. [32] GOLLOB J A,SCIAMBI C J,PETERSON B L,et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high~dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma[J] . Clin Cancer Res,2006,12(15):4619-4627. [33] POHLMANN P,DILEONE L P,CANCELLA A I,et al. Phase II trial of cisplatin plus decitabine,a new DNA hypomethylating agent,in patients with advanced squamous cell carcinoma of the cervix[J] . Am J Clin Oncol,2002,25(5):496-501. [34] MOMPARLER R L,AYOUB J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer[J] . Lung Cancer,2001,34 (Suppl 4):111-115. [35] SCHWARTSMANN G,SCHUNEMANN H,GORINI C N,et al. A phase I trial of cisplatin plus decitabine,a new DNA-hypomethylating agent,in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer[J] . Invest New Drugs,2000,18(1):83-91. [36] DacogenTM (decitabine) for Injection[EB/OL] . 2006(2006-12-08).http://www.yxlist.com/cgi/generic 4/dacogen.htm. [37] HURTUBISE A,MOMPARLER R L. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells[J] . Cancer Chemother Pharmacol,2006,58(5):618-625.

Accesses

Citation

Detail

段落导航
相关文章

/